A recent concern of MS is the relationship with prothrombosis and increased CVD risk. In a prothrombotic state, a dangerous clot can form if a vulnerable plaque ruptures. Fibrinolysis impairment may cause vascular damage and initiate obstructions of the circulatory system inherently increasing CVD risk. Prothrombosis in people with MS may be due to the negative synergy associated to smaller amounts of tissue plasminogen activator secreted in correlation with higher concentrations of the adipokine plasminogen activator inhibitor-1 being secreted from the outcome of insulin resistance and glucose intolerance. The enzyme tissue plasminogen activator catalyzes the conversion of plasminogen to plasmin, an enzyme essential to fibrinolysis, while plasminogen activator inhibitor-1 is the primary inhibitor of tissue plasminogen activator. If plasminogen activator inhibitor-1 and tissue plasminogen activator levels attributed to prothrombosis remain unchanged, repeated bouts of unwanted coagulation may ensue, which when combined with atherosclerosis increases the chance of a cardiovascular event. While prothrombosis is a major risk factor for CVD, as a thrombus is virtually considered a requisite for the most fatal type of CVD (i.e. myocardial infarction), prothrombotic states shouldnt raise incidence for T2DM. Other conditions of MS though, such as CO, IR, and systemic inflammation, increase the risk of both CVD and T2DM. Nevertheless, all conditions of MS should be taken seriously and attempted to be alleviated as they are thought to work in synergistic fashion to markedly increase incidence of T2DM and/or CVD.
Last date updated on July, 2014